Literature DB >> 19837910

Clinical, genetic, and enzymatic characterization of P450 oxidoreductase deficiency in four patients.

Taninee Sahakitrungruang1, Ningwu Huang, Meng Kian Tee, Vishal Agrawal, William E Russell, Patricia Crock, Nuala Murphy, Claude J Migeon, Walter L Miller.   

Abstract

CONTEXT: P450 oxidoreductase (POR) deficiency causes disordered steroidogenesis; severe mutations cause genital ambiguity in both sexes plus the Antley-Bixler skeletal malformation syndrome, whereas mild mutations can cause adult infertility.
OBJECTIVE: We describe four patients with POR deficiency and identify and characterize the activities of their mutations. A 46,XY male with micropenis and two 46,XX female infants with genital ambiguity presented with skeletal malformations, and a 46,XX adolescent presented with primary amenorrhea, elevated 17alpha-hydroxyprogesterone, and low sex steroids.
METHODS: The coding regions of the POR gene were sequenced, and the identified mutations were recreated in human POR cDNA expression vectors lacking 27 N-terminal residues. POR and human P450c17 were expressed in bacteria. POR activity was measured by four assays: reduction of cytochrome c, oxidation of reduced nicotinamide adenine dinucleotide phosphate, and support of the 17alpha-hydroxylase and 17,20 lyase activities of P450c17.
RESULTS: All four patients were compound heterozygotes for POR mutations, including five novel mutations: L577R, N185K, delE217, and frameshift mutations 1363delC and 697-698insGAAC. N185K and delE217 lacked measurable activity in the assays based on P450c17 but retained partial activity in the assays based on cytochrome c. As assessed by V(max)/Km, L577R supported 46% of 17alpha-hydroxylase activity but only 27% of 17,20 lyase activity. Computational modeling of these novel mutants revealed the structural basis for their reduced or absent activities.
CONCLUSION: These patients illustrate the broad clinical spectrum of POR deficiency, including amenorrhea and infertility as the sole manifestation. POR assays based on P450c17 correlate well with hormonal and clinical phenotypes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837910      PMCID: PMC2795645          DOI: 10.1210/jc.2009-1460

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  40 in total

1.  Evidence for digenic inheritance in some cases of Antley-Bixler syndrome?

Authors:  W Reardon; A Smith; J W Honour; P Hindmarsh; D Das; G Rumsby; I Nelson; S Malcolm; L Adès; D Sillence; D Kumar; C DeLozier-Blanchet; S McKee; T Kelly; W L McKeehan; M Baraitser; R M Winter
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

2.  Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase.

Authors:  Amit V Pandey; Petra Kempná; Gaby Hofer; Primus E Mullis; Christa E Flück
Journal:  Mol Endocrinol       Date:  2007-06-26

3.  Preimplantation genetic diagnosis of P450 oxidoreductase deficiency and Huntington Disease using three different molecular approaches simultaneously.

Authors:  Trinitat M Alberola; Rosa Bautista-Llácer; Esther Fernández; Xavier Vendrell; Manuel Pérez-Alonso
Journal:  J Assist Reprod Genet       Date:  2009-07-21       Impact factor: 3.412

4.  Cholesterol metabolism: the main pathway acting downstream of cytochrome P450 oxidoreductase in skeletal development of the limb.

Authors:  Katy Schmidt; Catherine Hughes; J A Chudek; Simon R Goodyear; Richard M Aspden; Richard Talbot; Thomas E Gundersen; Rune Blomhoff; Colin Henderson; C Roland Wolf; Cheryll Tickle
Journal:  Mol Cell Biol       Date:  2009-03-09       Impact factor: 4.272

5.  P450 oxidoreductase expressed in rat chondrocytes modulates chondrogenesis via cholesterol- and Indian Hedgehog-dependent mechanisms.

Authors:  Alexandra Aguilar; Shufang Wu; Francesco De Luca
Journal:  Endocrinology       Date:  2009-03-05       Impact factor: 4.736

6.  Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency.

Authors:  Eli Hershkovitz; Ruthi Parvari; Stefan A Wudy; Michaela F Hartmann; Larissa G Gomes; Neta Loewental; Walter L Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-06-17       Impact factor: 5.958

7.  Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19.

Authors:  Vishal Agrawal; Ningwu Huang; Walter L Miller
Journal:  Pharmacogenet Genomics       Date:  2008-07       Impact factor: 2.089

8.  Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients.

Authors:  Maki Fukami; Gen Nishimura; Keiko Homma; Toshiro Nagai; Keiichi Hanaki; Ayumi Uematsu; Tomohiro Ishii; Chikahiko Numakura; Hirotake Sawada; Mariko Nakacho; Takanori Kowase; Katsuaki Motomura; Hidenori Haruna; Mihoko Nakamura; Akira Ohishi; Masanori Adachi; Toshihiro Tajima; Yukihiro Hasegawa; Tomonobu Hasegawa; Reiko Horikawa; Kenji Fujieda; Tsutomu Ogata
Journal:  J Clin Endocrinol Metab       Date:  2009-03-03       Impact factor: 5.958

Review 9.  Genetic and clinical features of p450 oxidoreductase deficiency.

Authors:  Rachel R Scott; Walter L Miller
Journal:  Horm Res       Date:  2008-02-06

10.  Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P.

Authors:  Vivek Dhir; Hannah E Ivison; Nils Krone; Cedric H L Shackleton; Aidan J Doherty; Paul M Stewart; Wiebke Arlt
Journal:  Mol Endocrinol       Date:  2007-05-15
View more
  28 in total

1.  Consequences of POR mutations and polymorphisms.

Authors:  Walter L Miller; Vishal Agrawal; Duanpen Sandee; Meng Kian Tee; Ningwu Huang; Ji Ha Choi; Kari Morrissey; Kathleen M Giacomini
Journal:  Mol Cell Endocrinol       Date:  2010-11-09       Impact factor: 4.102

2.  Electron transfer by human wild-type and A287P mutant P450 oxidoreductase assessed by transient kinetics: functional basis of P450 oxidoreductase deficiency.

Authors:  Yi Jin; Mo Chen; Trevor M Penning; Walter L Miller
Journal:  Biochem J       Date:  2015-05-15       Impact factor: 3.857

Review 3.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Authors:  Walter L Miller; Richard J Auchus
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

4.  Clinical and genetic analysis of cytochrome P450 oxidoreductase (POR) deficiency in a female and the analysis of a novel POR intron mutation causing alternative mRNA splicing : Overall analysis of a female with POR deficiency.

Authors:  Tao Zhang; Zhou Li; Xinling Ren; Bo Huang; Guijin Zhu; Wei Yang; Lei Jin
Journal:  J Assist Reprod Genet       Date:  2020-07-28       Impact factor: 3.412

5.  Identification of six novel P450 oxidoreductase missense variants in Ashkenazi and Moroccan Jewish populations.

Authors:  Mária Tomková; Christopher C Marohnic; David Gurwitz; Ondřej Seda; Bettie Sue Siler Masters; Pavel Martásek
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

6.  Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase.

Authors:  Vishal Agrawal; Ji Ha Choi; Kathleen M Giacomini; Walter L Miller
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

Review 7.  Congenital Adrenal Hyperplasia.

Authors:  Selma Feldman Witchel
Journal:  J Pediatr Adolesc Gynecol       Date:  2017-04-24       Impact factor: 1.814

8.  Nonclassic congenital adrenal hyperplasia.

Authors:  Selma Feldman Witchel; Ricardo Azziz
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-30

9.  Disorder of sex development as a diagnostic clue in the first Spanish known newborn with P450 oxidoreductase deficiency.

Authors:  Dunia Sánchez-Garvín; Sonia Albaladejo; Begoña Ezquieta; Raquel Corripio
Journal:  BMJ Case Rep       Date:  2013-07-22

10.  Differential Frequency of CYP2R1 Variants Across Populations Reveals Pathway Selection for Vitamin D Homeostasis.

Authors:  Alex Casella; Caela Long; Jingman Zhou; Meizan Lai; Lauren O'Lear; Ilana Caplan; Michael A Levine; Jeffrey D Roizen
Journal:  J Clin Endocrinol Metab       Date:  2020-05-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.